HypoPet eyes key partnerships to advance pet VLP vaccines

摘要

Established in 2013 as a spin-off company from the University of Zurich, HypoPet aims to transform effective human medicines into safe, affordable and long-lasting therapies for pets. Animal Pharm analyst Daniel Willis spoke to HypoPet chief executiveGary Jennings to find out more about the company's next steps, as it looks to advance its product candidates.HypoPet develops vaccines that consist of virus-like particles (VLPs) as a backbone, with disease-associated molecules on the surface. These molecules are fixed on the VLP surface via a chemical linker. When vaccinated, the VLP building block of the vaccine simulates a viral attack, causing a powerful antibody response against the selected disease-related molecule on its surface.